Page 1

2019 PAINWeek Abstract Posters 1

Expert Consensus on the Optimization of Cannabinoids and Opioids for Chronic Pain Control

2

A Co-Crystal of Tramadol-Celecoxib in a 1:1 Molecular Ratio Produced Synergistic Antinociceptive Effects in a Postoperative Pain Model in Rats

3

The Unique Physiochemical Profile of Co-Crystal of Tramadol-Celecoxib Optimizes Pharmacokinetic and Pharmacodynamic Synchronization: Structural Properties, Differential Dissolution Behavior and Pharmacokinetic Parameters

4

Co-Crystal of Tramadol-Celecoxib: Efficacy and Safety Results from a Dose-Finding, Randomized, Double-blind, Multicenter, Phase II Clinical Trial in Patients with Moderate-To-Severe Acute Pain Due To an Oral Surgical Procedure

5

Implementation of Pragmatic Guidelines for Inpatient Opioid Management in a Regional Multi-Hospital System

6

Tolperisone, a Novel Muscle Relaxant, does not Impair Driving, While Cyclobenzaprine Results in Driving Impairment Potentially Due to Effects on Drowsiness

7

Ubrogepant Is Effective for the Acute Treatment of Migraine in Patients With an Insufficient Response to Triptans

8

The effect of food on the pharmacokinetic profile of a new abuse-deterrent oxycodone IR formulation compared to a marketed reference formulation

9 10

Evaluation of the intranasal abuse potential of a new abuse-deterrent oxycodone IR formulation compared to oxycodone powder Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine

11

The Burden of Pain Symptoms: A prototype for citizens of British Columbia

12

Role of Tapentadol in Central Pain Condition: A Case Report

13

Exploratory in-vitro mastication to assess the potential accelerated release of Fentanyl from a transdermal patch

14

Opioid Use among People with Migraine: Results of the OVERCOME Study (2017-6229-002)

15

Cannabidiol: A Retrospective Review of Patient Outcomes for Pain, Sleep, Anxiety, Depression and Function

16

Does Cognitive Behavioral Therapy Increase Acceptance of Chronic Pain? A Practice-Based Evaluation amongst Veterans

17

An Examination of the Impact of Acceptance & Commitment Therapy on Pain-Related Acceptance in Veterans

18

A Randomized Control Trial of Multimedia Interventions to Improve Pain Education among Veterans with Chronic, Non-cancer Pain

19

Improved Functionality, Pain Relief, and Satisfaction in Patients Treated with Ubrogepant vs Placebo: Results from 2 Single-Attack Phase 3 Studies, ACHIEVE I and II

20

Functionality Study of the Pill-SafeTM Digital Health System to Assess Real Time Mechanical, Clinical Practicality, and Utility including Instantaneous Analytical Data on Drug Abuse Tendencies and Adherence: Alpha Usability Test

21

Exploration of Body Ownership, Agency and Heat Pain Perception in Virtual Reality (Vr)

22 23

A Serious Immersive Virtual Reality Game for Promoting Chronic Arthritis Pain Patients' General Physical Activity and Range Of Motion Does Immersive Virtual Reality Provide Modulate Chronic Pain: A Longitudinal Study Design

24

The design and evaluation of AS IF for sharing chronic pain patients’ experience in virtual reality settings

25

“I’ve got the power!” People in pain and their journey through coaching

26

Impact of Galcanezumab on Total Pain Burden: Findings from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache Features of Episodic Cluster Headache in the Real World Setting: Clinical Characteristics from a Large, Multi-National, CrossSectional Survey DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the acute treatment of episodic migraine: Efficacy results from two phase III randomized, double-blind, placebo-controlled studies

27 28 29

Safety and tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the acute treatment of episodic migraine: Safety results from two phase III randomized, double-blind, placebo-controlled studies

30

A Randomized, Controlled, Crossover Study to Assess the Abuse Potential of Lasmiditan

31

Safety and Efficacy of Lasmiditan in Patients with Cardiovascular Risk Factors: Results from Two Phase 3 Trials for Acute Treatment of Migraine Subcutaneous Tanezumab For Osteoarthritis: A 24-Week Phase 3 Study with A 24-Week Follow Up

32


33

Facet joint: a new path for the epidural steroid injection in the patients taking antiplatelets and anticoagulants

34 35

Assessing Conformance of Healthcare System Policies and Procedures with Generally Accepted Best Practice Guidelines on Preventing Diversion of Controlled Substances Counterfeiting of Alprazolam Tablets: A Growing Problem with Disastrous Consequences

36

Best Practices for Optimal Waste Segregation Management in the Healthcare System

37

Ketamine Infusions: An Opioid Reduction Strategy in Trauma Patients with Rib Fractures

38

The Beginning: Defining Quality Metrics to Support Safe and Effective Pain Management

39

Phase 1 Trial Results for NTM-001 (Novel Alcohol-free Formulation for Continuous 24h IV Infusion of Ketorolac from a Pre-Mixed Bag) Meet Predictions of PK/PD Modeling Preliminary Resultsfor Elderly Subjects with/without Renal Impairment of a Randomized, Controlled Pharmacokinetic Study of NTM-001 Compared with an IV Bolus Regimen of Ketorolac Phase 1 Trial Results for NTM-001 (Novel Alcohol-free Formulation for Continuous 24h IV Infusion of Ketorolac from a Pre-Mixed Bag) Meet Targets of Model-Informed Development

40

Preliminary Results for Healthy Young Volunteers of a Randomized, Controlled Pharmacokinetic Study of NTM-001 Compared with a Standard Bolus Regimen of IV Ketorolac

41

NTM-001: A Novel, Alcohol-free Formulation of Ketorolac Tromethamine in a Pre-Mixed Bag for Intravenous Continuous 24h Infusion; A Potential Alternative to Opioids to Treat Acute Moderately Severe Post-Operative Pain

42

43

NTM-001 – Evidence-Based and Modeling-Supported Development of a Novel Alternative to Opioids for Moderately Severe Acute Post-Operative Pain; A Literature Review Related to Safety and Efficacy Studies of Continuous IV Infusion of Ketorolac Tromethamine and the Proposed Dosing Regimen of NTM-001 The Behavioral Health Alternative Pain Program and the Integration of Clinical Pharmacy

44

TrkA antagonists as a new therapeutic option for post-operative pain

45

Clinically relevant improvements in knee osteoarthritis pain with diclofenac sodium gel 1%

46 47

Efficacy and Safety Profile of a Topical Methyl Salicylate and Menthol Patch in Adult Patients with Mild to Moderate Muscle Strain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study Shorter Drug Testing Intervals are Associated with Improved Drug Misuse Rates

48

Educating Patients Receiving Prescription Opioids About Opioid Withdrawal

49 50

Lofexidine for the Management of Opioid Withdrawal Syndrome in a Patient Discontinuing Opioid Therapy for Chronic Pain Long-term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine Attacks

51

Reversion from chronic to episodic migraine in patients with documented inadequate response to 2-4 classes of migraine preventive treatments: results of the randomized, placebo-controlled FOCUS study Buprenorphine Buccal Film Improves Patient Global Impression of Change and Reduces the Prevalence of Anxiety and Insomnia in Patients with Chronic Low Back Pain Consistent Efficacy of Buprenorphine Buccal Film in Opioid-Naive and Opioid-Experienced Patients with Moderate to Severe Chronic Low Back Pain

52 53 54

Aging High: Geriatric Patients with Opioid Use Disorder

55

Treating Pain in Patients with Dementia and How It Might Relieve Agitation

56

Fentanyl and the Southwestern Border

57

Reversing Opioid-Induced Respiratory Depression and Stemming Opioid Overdose Deaths: What Do We Do When Naloxone (Narcan) Is Not Enough?

58

Recovery from Plantar Heel Pain through the Fascial Distortion Model: A Pilot Study

59

Study of the effect of Lavender and Rosemary extracts on the modulation of T-type calcium channels in neuropathic pain

60 61

Withdrawn Withdrawn

62

ZTLidoÂŽ (Lidocaine Topical System) 1.8% has superior adhesion compared to generic Mylan Lidocaine Topical patch 5%

63 64

Understanding the Patient Perspective: Benefits and Risks of Pain Treatment for Osteoarthritis and Chronic Lower Back Pain Effects of Adverse Childhood Experiences on Pain Interference and Anxiety in an Integrative Chronic Pain Clinic

65

Efficacy of fremanezumab in patients with migraine and documented inadequate response to 2, 3, or 4 classes of migraine preventive treatments: results of the international, multicenter, randomized, placebo-controlled FOCUS study

66

Withdrawn


67

Prescription drug monitoring program (PDMP) utilization and outcomes within the West Palm Beach Veterans Affairs (VA) Healthcare System

68

Anti-infective Prescribing Practices in Hospice Patients

69

Psychological pain in transgender people: Understanding suicide risk and prevalence

70

Onset and Maintenance Of Efficacy Of Subcutaneous Tanezumab In Patients With Moderate To Severe Osteoarthritis Of The Knee Or Hip

71

Dangerous Bradycardia and QT interval elongation in a Patient on Buprenorphine-Naloxone Therapy: A Case Report

72

Evaluation of the Number of Migraine Headache Days and Hours in a Multicenter, Open-Label, Long-Term, Safety Study of DFN02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM) for the Acute Treatment of Migraine

73

Triptan-Related Adverse Events in a Multicenter, Open-Label, Long-Term, Safety Study of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM) for the Acute Treatment of Migraine

74

Randomized, Double-Blind, Pilot Study Comparing 3 mg Subcutaneous Sumatriptan With 6 mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector (Zembrace® SymTouch®) for the Acute Treatment of Rapidly Escalating Migraine Attacks

75

Breaking barriers to care: learnings from Pain BC's Pain Support Line

76

Incidence and Severity of Constipation in Patients Treated for Chronic Pain With Buprenorphine Buccal Film

77

Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Patients With Chronic Non-cancer Pain: Subgroup Analyses by Opioid Dose

78

PMHNPs and Pain: A Call for Precepting the Psychiatric Mental Health Nurse Practitioner Student in Interdisciplinary Pain Management Teams

79

Withdrawn

80

Virtual Embodiment in Virtual Reality Reveals Mirror Visual Feedback Influences on Pain-Free Range of Motion

81

Efficacy and safety of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications: results of the multicenter, randomized, placebo-controlled FOCUS study Dysgeusia Rates in a Multicenter, Open-Label, Long-Term, Safety Study of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM) for the Acute Treatment of Migraine

82 83

The Effect of Migraine Headache Intensity on the Efficacy of Low-Dose (3 mg) Sumatriptan Injection (DFN-11; Zembrace® SymTouch®) in the Acute Treatment of Episodic Migraine Attacks: The RESTOR Study

84

Pharmacokinetics of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM) Compared with Intranasal Sumatriptan 20 mg in Healthy Adults

85

Medication Use Evaluation of Opioid Prescribing Patterns at Eskenazi Health

86

A Call for diligent Cannabidiol Research: Discrepancies between Knowledge and Beliefs of Healthcare Professionals

87

Characterization of Individuals with Osteoarthritis in the United States and Their Use of Prescription and Over-the-Counter Treatments

88

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect of Extended-Release Triamcinolone: Phase 3 Post-Hoc Sensitivity Analysis Attrition of Treatment-Emergent Adverse Events by Methylnaltrexone in Patients with Chronic Noncancer Pain and Opioid-Induced Constipation Treatment with Methylnaltrexone in Patients with Opioid-Induced Constipation with or Without Active Cancer: Effects of the Initial Dose Based on 3 Pooled Clinical Studies Evaluation of a Pharmacist-Led Pain Care Management Pilot Program

89 90 91 92 93 94 95 96

Long-term efficacy of fremanezumab in patients with chronic migraine with concomitant preventive medication use Long-term response rates in chronic and episodic migraine patients with concomitant preventive medication use: results from 1year study Sustained response to erenumab over time in patients with episodic migraine Identifying Sociodemographics and Symptoms Associated with Emergency Department and Urgent Care Use in People with Migraine: Survey Results from Migraine in America Symptoms and Treatment Study Headache Treatment Pattern and Co-morbid Health Burden Associated with Emergency Department and Urgent Care Use in People with Migraine: Survey Results from Migraine in America Symptoms and Treatment Study

97

One-Year Incidence of Migraine in the US Population: Results from the Migraine in America Symptoms and Treatment (MAST) Study

98

Identification of Pain, Activity Level, and Neuropsychiatric Symptoms in Chronic Pain Patients Receiving Joint and Soft Tissue Corticosteroid Injections


99

The Effect of the Prescription Drug Monitoring Program on Emergency Department Opioid Prescribing Habits

100

Evaluation of the Efficacy of Intra-articular CNTX-4975 in Subjects with Knee Osteoarthritis: Results From an 8-Week Study

101

Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of the Selective Oral CCR2 Antagonist CNTX-6970 in Healthy Subjects

102

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of the Novel Oral CCR2 Antagonist, CNTX-6970, in Healthy Volunteers

103

Evaluation of the Selective Oral CB2 Agonist CNTX-6016 for the Treatment of Neuropathic Pain: Pharmacokinetic, Efficacy, and Safety Findings from Preclinical Studies

104

Evaluation of the Selective Oral CCR2 Antagonist CNTX-6970 in the Treatment of Osteoarthritis Pain; Results from Preclinical Studies of Pharmacokinetics and Efficacy

105 106

Measuring Quality of Initial Opioid Prescribing: Pilot Testing Results for Pharmacy Quality Alliance in Medicaid, Medicare and Commercially Insured Patients Analgesic efficacy of combined Pectoral nerve blocks (PECS I & II) in surgeries for Breast carcinoma

107

Is administration of 5% dextrose reduces post operative nausea and vomiting (PONV) In laparoscopic cholecystectomy ?

108 109

Opioid Use for the Treatment of Osteoarthritis among Primary Care Physicians, Rheumatologists, and Orthopedic Surgeons Measuring the Severity of Osteoarthritis: Do patients and physicians agree?

110

Analysis of testosterone use in male veterans in the setting of opioid cessation or down titration

111

Demographics, Headache Characteristics, and Other Factors Associated With Opioid Use in People With Migraine: Results From the CaMEO Study

112 113

Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in episodic migraine patients with acute medication overuse at baseline: results of a 1-year study Abuse of XTAMPZA ER is rare relative to other opioid analgesics

114

The diversion and street price of XTAMPZA® ER relative to other prescription opioids

115

Perception XTAMPZA® ER and other abuse-deterrent opioid formulations on the internet

116

Dramatic Relief of Non-Combat PTSD after Stellate Ganglion Block: A Case Report

117

Autologous, Micro Fragmented Adipose Tissue as a Treatment for Bilateral Chronic Shoulder Pain in a Paraplegic Individual

118

‘Deuterated’ Drugs: Application to Analgesics?

119

Is Some e-Cigarette Use, Like Some Cigarette Use, Chronic-Pain Coping?

120

Buprenorphine: Unique Supraspinal Mechanism of Analgesic Action?

121

Partial Agonism: Basic Principles and Clinical Implications

122

The Concept of a ‘μ-Load’

123

Treating Opioid-Induced Constipation (OIC): Is CYP450 Drug Interaction a Concern?

124

Benzodiazepines and Opioids

125

Prevalence of Gastric Ulcer Disease (UD) and Association with NSAID Use among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment (MAST) Study

126 127

Most Bothersome Associated Migraine Symptom: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study Poor Acute Treatment Optimization and Frequent Nausea in Episodic Migraine (EM) are Associated with New Onset Chronic Migraine (CM): Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study Women with migraine vary in time to peak headache pain intensity, functional impairment and pain interference based on menstrual migraine status: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study

128 129

Association and Impact of Monthly Migraine Headache Frequency and Pain Intensity on Comorbidities and Concomitant Health Conditions: Results from the Migraine in America Symptoms and Treatment (MAST) Study

130

Impact of Monthly Headache Day Frequency on Work Productivity and Impairment in Non-Work Activities among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment Study

131

Comorbidity, Treatment Patterns, And Economic Burden of Primary Headache Disorders: An Administrative Claims Data Analysis

132 133

Recurrent Pain Abdomen in young Children Impact of a Health System Wide Opioid Stewardship Program on Prescribing Practices Following Orthopedic Surgery

134

Characteristics of Patients with Migraine Initiating Galcanezumab for the Preventive Treatment of Migraine

135

Pain relief after Lower Segment Cesarean Section: Comparison between Tramadol and Paracetamol


136

What Matters Most in the Diagnosis and Monitoring of Osteoarthritis by Physician Specialty?

137

Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in chronic migraine patients with acute medication overuse at baseline: results of a 1-year study Long-term efficacy of fremanezumab in chronic and episodic migraine patients with acute medication overuse at baseline: results of a 1-year study Tapentadol is the least common finding in admission urine drug-test results at a substance-use treatment facility in Ohio Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a US Commercially Insured Population

138 139 140 141

Sustained response to erenumab over time in patients with chronic migraine

142

The Slipped Rib Syndrome in an Active Duty Military Member – Long Term Disability followed by Successful Return to Work After Pulsed Radiofrequency at the T12 Dorsal Root Ganglion Combined with Physical and Psychological Therapy A Functional Restoration Program for Active Duty Military Personnel with Chronic Pain: Comparing Patient Reported Effectiveness Relative to Standard Medical Treatment at the Pain Clinic

143 144

An Assessment of the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Cannabinoids in Adult Outpatients with Chronic Pain

145

Patient and Healthcare Provider Perspectives on the Unmet Needs and Stigma of Migraine

146

A cross-sectional survey evaluating questions on patient motivation for use of prescribed opioids to assist in identifying Opioid Use Disorder Online Continuing Medical Education Program Improves Knowledge Among Neurologists and Primary Care Physicians Regarding the Management of Opioid Withdrawal Syndrome

147 148

DHEA Deficiency in Fibromyalgia

149

How do you feel about Cannabidiol? Lessons from a survey in a pain clinic environment

150

Can CBD Reduce the Use of Pain Medication? Insights from a Survey in a Pain Clinic Environment

151

155 156

Chronic pain treatment satisfaction in musculoskeletal disease: differences between osteoarthritis and chronic low back pain in medication switching, opioid use, and utilization of non-drug treatments A Functional Restoration Program for Active Duty Service Members with Chronic Pain: An Examination of Physical Function Assessments Retrospective Analysis of Opioid Prescription Surrounding Treatment with Hylan G-F 20 in Patients with Osteoarthritis of the Knee Retrospective Analysis of Intra-Articular Corticosteroid Injections Surrounding Treatment with Hylan G-F 20 in Patients with Osteoarthritis of the Knee A Randomized Placebo-Controlled pilot Study of a Topical Herbal Analgesic for the Management of Chronic Musculo-skeletal Pain The association of sarcopenia with low back pain and lumbar spine degeneration

157

Relationship between obesity and lumbar spine degeneration

158

Radiation Protection Effect of Lead Curtain during Fluoroscopic Guided Procedure

159

Promoting Physical Activity and Movement for Arthritis Patients through a Virtual Reality Game

160

FitViz-Ad: A Non-Intrusive Reminder to Support and Encourage Rheumatoid Arthritis Patients with Physical Activity

161

Wearable Transcutaneous Electrical Nerve Stimulation is Associated with Improved Objective Sleep Measures in Poor Sleepers with Chronic Knee Pain

162 163

Clinical and Treatment Variables Associated with Effectiveness of Wearable Transcutaneous Electrical Nerve Stimulation in Individuals with Chronic Knee Pain The Social and Functional Implications of High versus Low Dose Opioids on Chronic Non-Cancer Pain

164

Side Effect Profile of Oral CBD Capsules in a Pain Management Population, 10 month Data Set

165

Patient Satisfaction with Chronic Pain Management and Correlations with Treatment in a Pharmacist-Physician Collaborative Care Model Within Primary Care

166 167

CBD Use at a Pain Management Clinic, Our Experience With CBD as a Mechanism for Polypharmacy Reduction, 10 month data set Use of a specific type of CBD as a method for opioid reduction in patients on chronic opioid therapy, our experience at a pain management center, 10 month data set

168

A challenging case of sciatica and the value of dynamic EMG

169

An Analysis of Biomarkers in Chronic Pain Patients

170

Using Comfort Menu to Impact Pain Experience

171

Deep Heat: Shortwave Diathermy in Pain Management

152 153 154


172

Study Design of a Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory Depression, Tolerability, and Pharmacokinetics

173

Evaluation of DFN-15, a liquid oral formulation of celecoxib, in acute post-operative pain following extraction of third mandibular molar teeth Perceived effectiveness of DFN-15 (celecoxib oral solution) in acute pain following surgery for extraction of impacted wisdom teeth

174 175

Single Dose Pharmacokinetics of DFN-15, a Novel Liquid Oral Formulation of Celecoxib, in subjects experiencing acute post-surgical pain following extraction of impacted wisdom teeth

Â ď ś All abstract titles and poster numbers are correct at the time of printing

Profile for PAINWeek

List of PAINWeek 2019 Abstract Titles and Poster Numbers  

List of PAINWeek 2019 Abstract Titles and Poster Numbers  

Profile for painweek